01 June 2010
Med Sci Monit 2010; 16(6): BR193-196 :: ID: 880608
Background: Tigecycline is a new glycylcycline with broad-spectrum activity. Among these new agents, tigecycyline is unique in generally having good activity against Gram-negative bacteria. Tigecycline has been approved for the treatment of complicated intra-abdominal infections and complicated skin and skin structure infections. Tigecycline had good activity against most ESBL-producing Enterobacteriaceae and may be a therapeutic alternative to carbapenems in some infections caused by ESBL-producing isolates, many of which are also multiresistant to quinolones, aminoglycosides, and classical tetracyclines.
Material/Methods: One hundred and eight clinical isolates of Klebsiella spp. (64 K. pneumoniae and 44 K. oxytoca) were included. The susceptibility to selected antibiotics was tested by the disk-diffusion method. Tigecycline’s MIC was determined by the Etest.
Results: Of all the analyzed Klebsiella spp. strains, 31 (28.7%) produced ESBLs. Most of the Klebsiella spp. strains were susceptible to imipenem (100%), tigecycline (92.5%), and the combination of piperacilline and tazobactam (80.6%). Tigecycline exhibited high activity against Klebsiella strains, with MICs ranging from 0.19 to 4 microg/ml.
Conclusions: Tigecycline demonstrated excellent inhibitory activity against the analyzed strains. These data suggest that tigecycline, with an expanded broad-spectrum antimicrobial activity, may be an effective therapeutic option for the treatment of serious infections caused by Klebsiella strains.
Keywords: Klebsiella pneumoniae - metabolism, Klebsiella Infections - drug therapy, Klebsiella - metabolism, Enterobacteriaceae - metabolism, Drug Resistance, Multiple, Bacterial - drug effects, Drug Resistance, Bacterial, Cross Infection, Anti-Bacterial Agents - pharmacology, Microbial Sensitivity Tests, Minocycline - pharmacology, beta-Lactamases - metabolism
01 November 2023 : EditorialEditorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is Declared
Med Sci Monit 2023; 29:e942960
28 Nov 2023 : Clinical ResearchImpact of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography on Therapeutic Decisions and ...
Med Sci Monit In Press; DOI: 10.12659/MSM.942122
28 Nov 2023 : Clinical ResearchLong-Term Outcomes of Decompression and Grafting in Acute Pathological Proximal Femur Fractures in Children...
Med Sci Monit In Press; DOI: 10.12659/MSM.943031
27 Nov 2023 : Clinical ResearchComparison of Outcomes from Emergency Admissions to a Major Trauma Center in Turkey of 1646 Elderly Patient...
Med Sci Monit In Press; DOI: 10.12659/MSM.942916
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
14 Dec 2022 : Clinical ResearchPrevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels
Med Sci Monit 2022; 28:e937990
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292